Targeted treatments for complex, chronic heart diseases in cats and dogs
Next generation veterinary pain management for daily use
The world’s first veterinary registered PPI for canine gastric ulceration
Diagnostics for Gastric markers that indicate health and wellness
Tackling some of the most debilitating and chronic diseases of aging in companion animals
US product launch Q4 2023
EU launch Q1 2024
US product launch Q1 2024;
EU launch Q2 2024
US product launch Q1 2023
EU launch Q3 2023
US/EU product launch Q2 2023
Targeted treatments for complex, chronic heart diseases in cats and dogs
US product launch Q4 2023
EU launch Q1 2024
Next generation veterinary pain management for daily use
US product launch Q1 2024;
Q2 2024
The world’s first veterinary registered PPI for canine gastric ulceration
US product launch Q1 2023
EU launch Q3 2023
Diagnostics for Gastric markers that indicate health and wellness
US/EU product launch Q2 2023
Tackling some of the most debilitating and chronic diseases of aging in companion animals
Our research and development model is simple but effective.
We identify diseases in companion animals where there are no approved treatments.
We formulate novel solutions with species specific doses and presentations.
Our research team are bridging the gap between bench and bedside by conducting clinical trials that benefit client-owned dogs and cats.
The data collected is then used as clinical data for veterinary patients
We prove the safety and efficacy of our products to FDA and EMA requirements.
Our research and development model is simple but effective.
We identify diseases in companion animals where there are no approved treatments.
We formulate novel solutions with species specific doses and presentations.
Our translational research team are bridging the gap between bench and bedside by conducting clinical trials that benefit client-owned dogs and cats.
The data collected is then used both as clinical data for veterinary patients and preclinical data for human patients.
We prove the safety and efficacy of our products to FDA and EMA requirements.
We harness our extensive animal research to identify synergies in human medicine.
Keep up to date with our latest advancements and news as we continue to develop and commercialise medicines and diagnostics for use in companion animals.
TriviumVet appoint healthcare powerhouse Helen Ryan as Chairperson of their board. Helen takes the helm at an exciting time in the company's growth trajectory.
Dr. Joshua Sterns presentation from VMX 2023
%20(1).png)
Learn more about this exciting study which is open for recruitment. The "REVERSE" Feline Chronic Kidney Disease Study at The Ohio State Veterinary School.
